VIENNALAB - Established innovations in diagnostics

Monoclonal antibody therapies targeting EGFR work exceptionally well in metastatic colorectal cancer. However, certain mutations in the KRAS and NRAS genes prevent success of these therapies. The KRAS and NRAS StripAssays® rapidly identify the most relevant mutations in the KRAS and NRAS genes.

KRAS & NRAS Mutations

  • Epidermal Growth Factor (EGF) activates cell proliferation by binding to the EGF-Receptor (EGFR). This triggers a signal transduction pathway that includes the KRAS and NRAS proteins.
  • Inhibiting EGFR with monoclonal EGFR antibodies prevents activation of the relevant signal transduction pathway.
  • However, certain mutations in KRAS or NRAS result in permanent activation of parts of this pathway, rendering anti-EGFR therapies ineffective.
  • Identification of KRAS and NRAS mutations thus allows patient-specific treatment and prediction of tumor progression.





Product Details

KRAS StripAssay® ref5-590
NRAS XL StripAssay® ref5-620
KRAS XL StripAssay® ref5-680